GlassScriptPhysician profile
Kelliann Bachand
NPI 1700202967
$585.02
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.83 · 2022: $210 · 2023: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $326.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $132.37 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $91.23 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $67.43 | 2023 | Gemtesa |
| Daiichi Sankyo INC. | $63.91 | 2022-2023 | Injectafer |
| Pfizer INC. | $60.18 | 2021-2022 | |
| Agile Therapeutics, INC. | $38.87 | 2022 | |
| Myovant Sciences INC. | $37.89 | 2022 | |
| Astellas Pharma US INC | $37.28 | 2023 | Veozah |
| Exeltis, USA INC. | $36.62 | 2023 | Solosec, Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $19.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelliann Bachand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.